My HPRA: Register

The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Benylin Dry Coughs Syrup Diphenhydramine hydrochloride 14mg/5ml Dextromethorphan hydrobromide 6.5mg/5ml Levomenthol 2mg/5ml



JNTL Consumer Health I (Ireland) LimitedPA23490/004/001

Main Information

Trade NameBenylin Dry Coughs Syrup Diphenhydramine hydrochloride 14mg/5ml Dextromethorphan hydrobromide 6.5mg/5ml Levomenthol 2mg/5ml
Active SubstancesDiphenhydramine hydrochloride
Dextromethorphan hydrobromide
Levomenthol
Dosage FormSyrup
Licence HolderJNTL Consumer Health I (Ireland) Limited
Licence NumberPA23490/004/001

Group Information

ATC CodeR06AA Aminoalkyl ethers
R06AA52 diphenhydramine, combinations

Status

License statusAuthorised
Licence Issued29/09/1987
Legal statusProduct not subject to medical prescription
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to the general public
Conditions of Licence1. This product may cause drowsiness and patients receiving it should not drive or operate machinery unless it has been shown that their physical and mental capacity remains unaffected. 2. This product may potentiate the effects of alcohol and other central nervous system depressants. 3. Children receiving this product may become drowsy and should be carefully supervised in order to avoid accidental mishap. 4. If symptoms persist, consult your doctor. 5. Do not take this product for persistent or chronic cough such as occurs with smoking, asthma or emphysema or if cough is accompanied by excessive phlegm, unless directed by a doctor.
Marketing StatusMarketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back
Follow medicine

Print